POST Online Media Lite Edition


United Therapeutics announces executive leadership changes

Staff writer |
Silver Spring, Md., USA - April 29, 2016, Silver Spring, Md., USA - United Therapeutics Corporation, a biotechnology company, announced that Roger Jeffs has stepped down as president and co-chief executive officer and David Zaccardelli has stepped down as the EV and COO.

These departures will become effective June 26, 2016.

In addition, Dr. Jeffs will not stand for re-election to the company's Board of Directors when his current term expires at the 2016 Annual Meeting of Shareholders, which is to be held on June 21, 2016. Dr. Jeffs will become a Senior Advisor to the company.

Michael Benkowitz, the company's current Executive Vice President, Organizational Development, has been appointed by the Board to become the company's President and Chief Operating Officer, also effective June 26, 2016.

Mr. Benkowitz joined United Therapeutics in 2011 as the company's Executive Vice President, Organizational Development. In this role, he currently heads most companywide administrative functions, including human resources, information technology, corporate real estate and risk management.

He is also responsible for many of the company's business development efforts in organ transplantation, and oversees several of the company's key collaborations in this area.


What to read next

Helsinn Group: William Mann CEO of US operations
CMP Therapeutics appoints Neill Moray Mackenzie as CEO
Silence Therapeutics CEO Ali Mortazavi on leave of absence